Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Aug;64(8):2068-2071.
doi: 10.1007/s10620-019-05706-3.

Climbing New Mountains: How Antibodies Blocking α4β7 Integrins Tamed Eosinophilic Inflammation of the Intestinal Tract

Courtney L Olbrich  1   2 , Luke Simerly  1   2 , Edwin F de Zoeten  1   2   3 , Glenn T Furuta  1   2   3 , Lisa A Spencer  4   5   6
Affiliations
Editorial

Climbing New Mountains: How Antibodies Blocking α4β7 Integrins Tamed Eosinophilic Inflammation of the Intestinal Tract

Courtney L Olbrich et al. Dig Dis Sci. 2019 Aug.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Vedolizumab impacts leukocyte transmigration. The mucosal density of T lymphocytes and eosinophils increases in eosinophilic gastrointestinal disease inflammation. In the tissue space and upon stimulation, T lymphocytes can release cytokines that directly and indirectly promote eosinophil chemotaxis and activation. Vedolizumab blocks binding of the T lymphocyte-expressed gut-homing integrin α4β7 to its ligand mucosal vascular addressing cell adhesion molecule 1 (MAdCAM-1), specifically expressed on the endothelium of intestinal venules. Therefore, vedolizumab directly prevents the transmigration of T lymphocytes into the intestinal mucosa, indirectly impairing eosinophil recruitment and activation through preventing release of T cell-derived eosinophil-activating cytokines. Moreover, since α4β7 integrin is also expressed on eosinophils, vedolizumab may directly prevent eosinophil transmigration into intestinal tissues
See this image and copyright information in PMC

Comment on

References

    1. Grandinetti T, Biedermann L, Bussmann C, et al. Eosinophilic gastroenteritis: clinical manifestation, natural course, and evaluation of treatment with corticosteroids and vedolizumab. Dig Dis Sci. (Epub ahead of print). 10.1007/s10620-019-05617-3. - DOI - PubMed
    1. Attwood SE, Smyrk TC, Demeester TR, et al. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci. 1993;38:109–116. - PubMed
    1. Straumann A, Spichtin HP, Bernoulli R, et al. Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings. Schweiz Med Wochenschr. 1994;124:1419–1429. - PubMed
    1. Jung Y, Rothenberg ME. Roles and regulation of gastrointestinal eosinophils in immunity and disease. J Immunol. 2014;193:999–1005. - PMC - PubMed
    1. Forbes E, Murase T, Yang M, et al. Immunopathogenesis of experimental ulcerative colitis is mediated by eosinophil peroxidase. J Immunol. 2004;172:5664–5675. - PubMed

Supplementary concepts